1 | JOHNSON & JOHNSON MIDDLE EAST FZ LLC | 20203 | COVID-19 vaccine Janssen (Ad26.COV2-S
| Human | Foreign | COVID-19 vaccine (Ad26.COV2-S [recombinant]) | One dose (0.5 mL) contains: Adenovirus type 26
| H2021/CTD8692/20203EUA | Suspension For Injection | INTRAMUSCULAR | 24 months | | J07BX | Other viral vaccines | | | | Janssen Pharmaceutica NV, | Turnhoutseweg 30 B-2340 Beerse Belgium |
2 | MINISTRY OF HEALTH HEADQUARTERS (AFYA HSE) | 20471 | Novel Oral Poliomyelitis Vaccine Type 2 (nOPV2) | Human | Foreign | live attenuated Poliomyelitis virus type 2
| higher equal to 10^5.0 CCID_50 | H2021/CTD8797/20471EUA | Oral Drops, Suspension | ORAL | 12 Months | | J07BF01 | poliomyelitis oral monovalent live attenuated | | | | PT Bio Farma (Persero) | P.O. Box 1136 |
3 | MINISTRY OF HEALTH HEADQUARTERS (AFYA HSE) | 20414 | Tozinameran - COVID-19 mRNA vaccine (nucleoside
| Human | Foreign | Single-stranded, 5’-capped messenger RNA (mRNA)
| 30 micrograms of COVID-19 mRNA Vaccine (embedded
| H2021/CTD8748/20414EUA | Injection | INTRAMUSCULAR | 6 Weeks | | J07BX03 | Covid-19 vaccines | | | | BioNTech Manufacturing GmbH. | BioNTech Manufacturing GmbH. |
4 | SINOPHARM EAST AFRICA LIMITED | 20962 | COVID-19 Vaccine (Vero Cell), Inactivated | Human | Foreign | SARS-CoV-2, 19nCoV-CDC-Tan-HB02 Strain
| Acceptance range for antigen content:
| H2022/CTD9224/20962EUA | Injection | INTRAMUSCULAR | 18 months | | J07BX03 | Covid-19 vaccines | | | | Beijing institute of Biological Products CO..Ltd | No 6&9 Bo'xing 2nd Road Economic-Technological
|
5 | MINISTRY OF HEALTH HEADQUARTERS (AFYA HSE) | 20517 | COVID-19 Vaccine Moderna dispersion for injection
| Human | Foreign | messenger RNA (mRNA) (embedded in SM-102 lipid
| One dose (0.5 mL) contains 100 micrograms of
| H2021/CTD8835/20517EUA | Dispersion For Injection | INTRAMUSCULAR | 7 Days | | J07BX03 | Covid-19 vaccines | | | | LONZA AG | 3930 |
6 | MINISTRY OF HEALTH HEADQUARTERS (AFYA HSE) | 20276 | Vaxzevria suspension for injection | Human | Foreign | Chimpanzee Adenovirus encoding the SARS-CoV-2
| not less than 2.5 x 10^8 infectious units (Inf.U)
| H2021/CTD8663/20276EUA | Suspension For Injection | INTRAMUSCULAR | 6 Weeks | Suspension is colourless to slightly brown, clear
| J07BX03 | Covid-19 vaccines | Astraallen | SE151 85 Sodertalje Sweden | helen.m.shennan@astrazeneca.com | AstraZeneca Nijmegen B.V. Lagelandseweg 78
| Nijmegen B.V. Lagelandseweg 78 Nijmegen, 6545CG |
7 | MINISTRY OF HEALTH HEADQUARTERS (AFYA HSE) | 20408 | COVID-19 Vaccine (Vero Cell), Inactivated | Human | Foreign | Inactivated SARS-CoV-2 Virus (19nCoV-CDC-Tan-HB02
| (1) 0.5mL/syringe (Each pre-filled syringe
| H2021/CTD8749/20408EUA | Injection | INTRAMUSCULAR | 24 months | | J07BX03 | Covid-19 vaccines | | | | Beijing Biologiclas Products Institute Co.Ltd | Beijing Biologiclas Products Institute Co.Ltd |